Erectile Dysfunction Devices Market: Key Developments
In August 2022, Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys drug delivery technology and currently focused on sexual health and pain, announced the positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000, an investigational therapy for the treatment of Erectile Dysfunction (ED).
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients